Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript

Cancer Genetics and Cytogenetics

Volumn 174, Issue 2, 2007, Pages 111-115

  Pienkowska Grela, Barbara ^a   Woroniecka, Renata ^a   Solarska, Iwona ^b   Kos, Kinga ^b   Pastwińska, Anna ^a   Konopka, Lech ^b   Majewski, Miroslaw ^b  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GENE PRODUCT; IMATINIB;

ADULT; ARTICLE; CANCER REGRESSION; CASE REPORT; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE COURSE; EXON; FUSION GENE; GENE AMPLIFICATION; GENE DELETION; HUMAN; INTRON; KARYOTYPE; MALE; MOLECULAR EVOLUTION; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOID, CHRONIC; MALE; PHILADELPHIA CHROMOSOME; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 34247168516     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.11.021     Document Type: Article

References (20)

1. Rowley J.D. A new consistent abnormality in chronic myelogeneous leukemia identified by quinacrine fluorescence and giemsa staining. Nature 243 (1973) 290-293
2. Mitelman F, Johanson B, Mertens F, editors. Database of Chromosome Aberrations in Cancer, 2003. Available at: http://www.cgap.nci.nih.gov/chromosomes/Mitelman. Accessed November 2006.
3. Huret JL. +8 or trisomy 8. Atlas Genet Cytogenet Oncol Haematol. Available at: http://www.infobiogen.fr/services/chromcancer/Anomalies/tri8ID1017. Accessed November 2006.
4. Bacher U., Haferlach T., Hiddemann W., Schnittger S., and Kern W. Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet 157 (2005) 53-61
5. Melo J.V., Hughes T.P., and Apeprly J.F. Chronic myeloid leukemia. Hematology 2003 (2003) 132-152
6. Gambacorti-Passerini C.B., Gunby R.H., Piazza R., Galietta A., Rostagno R., and Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 4 (2003) 75-85
7. Sinclair P.B., Nacheva E.P., Leversha M., Telford N., Chang J., Reid A., Bench A., Champion K., Huntly B., and Green A.R. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95 (2000) 738-743
8. Cohen N., Rozenfeld-Granot G., Hardan I., Brok-Simoni F., Amariglio N., Rechavi G., and Trakhtenbrot L. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 128 (2001) 114-119
9. Bacher U., Schnitter S., Kern W., Hiddemann W., Haferlach T., and Schoch C. The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-AGBL positive acute lymphoblastic leukemia, and chronic myeloid leukemia. Haematologica 90 (2005) 558-559
10. Kim Y.R., Cho H.I., Yoon S.S., Park S., Kim B.K., Lee Y.K., Chun H., Kim H.C., and Lee D.S. Interpretation of submicroscopic deletions of the BCR or ABL gene should not depend on extra signal-FISH: problems in interpretation of submicroscopic deletion of the BCR or ABL gene with extra signal-FISH. Genes Chromosomes Cancer 43 (2005) 37-44
11. Jacson M.J., Surh L.C., O'Brien W.E., and Beaudet A.L. Assignment of the structural gene for argininosuccinate synthase to proximal mouse chromosome 2. Genomics 6 (1990) 545-547
12. Huntly B.J., Guilhot F., Reid A.G., Vassiliou G., Hennig E., Franke C., Byrne J., Brizard A., Niederwieser D., Freeman-Edward J., Cuthbert G., Bown N., Clark R.E., Nacheva E.P., Green A.R., and Deininger M.W. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 102 (2003) 2205-2212
13. Quintas-Cardama A., Kantarjian H., Talpaz M., O'brien S., Garcia-Manero G., Verstovsek S., Rios M.B., Hayes K., Glassman A., Bekele B.N., Zhou X., and Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105 (2005) 2281-2286
14. ISCN. An international system for human cytogenetic nomenclature. In: Mitelman F. (Ed) (1995), S. Karger, Basel
15. Van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G., Gottardi E., Rambaldi A., Dotti G., Griesinger F., Parreira A., Gameiro P., Diaz M.G., Malec M., Langerak A.W., San Miguel J.F., and Biondi A. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13 (1999) 1901-1928
16. Lee Y.K., Kim Y.R., Min H.C., Oh B.R., Kim T.Y., Kim Y.S., Cho I.H., Kim H.C., Lee Y.S., and Lee D.S. Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia. Cancer Genet Cytogenet 166 (2006) 65-73
17. Albiero E, Madeo D, Castaman G, Ghiotto R, Rodeghiero F. Detection of an atypical p210 b2-a3 fusion transcript in a Ph-positive patient. VIII Congresso Societa' Italiana di Genetica Umana, Le Meridien Chia Laguna, 2005.
18. Snyder D.S., McMahon R., Cohen S.R., and Slovak M.L. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory. Am J Hematol 75 (2004) 92-95
19. Cortes J., Talpaz M., Giles F., O'Brien S., Rios M.B., Shan J., Garcia-Manero G., Faderl S., Thomas D.A., Wierda W., Ferrajoli A., Jeha S., and Kantarjian H.M. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101 (2003) 3794-3800
20. Skorski T., Bellacosa A., Nieborowska-Skorska M., Majewski M., Martinez R., Choi J., Trotta R., Wlodarski P., Perrotti D., Chan T., Wasik M., Tsichlis P., and Calabretta C. Transformation of hematopoietic cells by BCR/ABL requires the activation of a PI-3k/Akt dependent pathway. EMBO J (1997) 16,20:6151-61